New drug ABBV-277 enters first human tests – no disease target yet
NCT ID NCT07136103
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage study tests a single dose of ABBV-277 in 32 healthy adults to see if it is safe and how the body handles it. Participants receive either the drug or a placebo by IV infusion. The goal is to measure side effects and drug levels in the blood, not to treat any illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Acpru /Id# 265681
Grayslake, Illinois, 60030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-277
What could go wrong
This is a very early, small study in healthy people, not patients. It only checks safety and drug levels, not whether the drug works for any disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.